FOLH1 and prostate carcinoma: Recently, they published results from a Phase I clinical trial showing that PSMA-targeting CAR-T cells co-expressing TGFβRDN were safe and effective in treating metastatic castration-resistant prostate cancer and significantly promoted CAR-T cell proliferation in vivo [82].